Last reviewed · How we verify
NCT03880422
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
NA trial testing Dietary Intervention in Cancer Survivor in 50 participants. Currently enrolling.
2 May 2029
Quick facts
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 2 May 2019 |
| Primary completion | 2 May 2029 |
| Estimated completion | 2 May 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dietary Intervention
- Educational Intervention
- Exercise Intervention
- Quality-of-Life Assessment
- Survey Administration
Conditions studied
- Cancer Survivor — all drugs for Cancer Survivor →
- Obesity — all drugs for Obesity →
- Overweight — all drugs for Overweight →
- Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
Sponsor
Roswell Park Cancer Institute
Who can join
18 and older, male only, with Cancer Survivor or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer.
Puig-Saenz C, Pearson JRD, Thomas JE, McArdle SEB. · · 2023 · cited 4× · PMID 37626597 · DOI 10.3390/biomedicines11082100 -
Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention.
Kumar NB, Parker N, Zhang J, Pow-Sang J, et al · · 2026 · PMID 42073599 · DOI 10.3390/cancers18081276
Verify or expand the search:
- PubMed search for NCT03880422
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dietary Intervention
Trials testing the same drug.
- NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
- NCT07091864 — Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma · NA · recruiting
- NCT06954584 — Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovari · Phase 3 · recruiting
- NCT06900439 — Exploring Glycemic Responses Through Continuous Monitoring in a Healthy Population · NA · completed
- NCT06336902 — Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorec · Phase 1 · recruiting
Other recruiting trials for Cancer Survivor
Currently open trials in the same condition.
- NCT06894849 — Text -Based Depression Screening Among Cancer Survivors · NA · recruiting
- NCT06868524 — Leading Healthy Eating and Activity Promotion Program · NA · recruiting
- NCT06574009 — Better Options for Chronic Cancer Pain · Phase 4 · recruiting
- NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
- NCT06814977 — An Acupuncture Study for Cancer Survivors With Joint Pain · NA · recruiting
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
- NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
- NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
- NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
- NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03880422 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880422.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing